Skip to content 
Impact BioMedical Inc. discovers, develops, and commercializes products and technologies to address unmet needs in human healthcare and wellness for specialty biopharmaceuticals, antivirals, antimicrobials, consumer healthcare, and wellness products in the United States. The company provides Linebacker, a platform of small molecule electrophilically enhanced polyphenol compounds with application in oncology, inflammatory disorders, and neurology; and Laetose technology that is derived from a unique combination of sugar and inositol, which can inhibit the inflammatory and metabolic response of sugar alone. It also develops functional fragrance formulation, a suite of functional fragrances containing specialized botanical ingredients with application as an antimicrobial, and as an additive in insect repellents, detergents, lotions, shampoo, fabrics, and other substances. In addition, the company develops Equivir/Equivir G technology, a novel blend of polyphenols, which have demonstrated antiviral effects for use in as health supplements and medications. Impact BioMedical Inc. was incorporated in 2018 and is based in Houston, Texas. Impact BioMedical Inc. operates as a subsidiary of DSS, Inc. more
| Time Frame | IBO | Sector | S&P500 |
|---|---|---|---|
| 1-Week Return | -7.78% | 1.07% | 0.74% |
| 1-Month Return | -9.55% | 1.46% | 1.28% |
| 3-Month Return | -5.47% | 3.51% | 3.6% |
| 6-Month Return | -27.19% | 15.29% | 7.31% |
| 1-Year Return | -79.25% | 7.7% | 11.97% |
| 3-Year Return | -84.51% | 21.02% | 72.07% |
| Dec '20 | Dec '21 | Dec '22 | Dec '23 | Dec '24 | 5YR TREND | |
|---|---|---|---|---|---|---|
| Total Revenue | - | 50.00K | 50.00K | 1.03M | 2.33M | [{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":2.14,"profit":true},{"date":"2022-12-31","value":2.14,"profit":true},{"date":"2023-12-31","value":44.19,"profit":true},{"date":"2024-12-31","value":100,"profit":true}] |
| Cost of Revenue | - | - | - | - | - | [{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true},{"date":"2024-12-31","value":"-","profit":true}] |
| Gross Profit | - | - | 50.00K | 1.03M | 2.33M | [{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":2.14,"profit":true},{"date":"2023-12-31","value":44.19,"profit":true},{"date":"2024-12-31","value":100,"profit":true}] |
| Gross Margin | - | - | 100.00% | 100.00% | 100.00% | [{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":100,"profit":true},{"date":"2023-12-31","value":100,"profit":true},{"date":"2024-12-31","value":100,"profit":true}] |
| Operating Expenses | 1.14M | 3.86M | 3.45M | 4.03M | 1.78M | [{"date":"2020-12-31","value":28.33,"profit":true},{"date":"2021-12-31","value":95.95,"profit":true},{"date":"2022-12-31","value":85.75,"profit":true},{"date":"2023-12-31","value":100,"profit":true},{"date":"2024-12-31","value":44.17,"profit":true}] |
| Operating Income | (1.14M) | (3.83M) | (3.40M) | (4.03M) | 551.66K | [{"date":"2020-12-31","value":-206.83,"profit":false},{"date":"2021-12-31","value":-694.82,"profit":false},{"date":"2022-12-31","value":-617.04,"profit":false},{"date":"2023-12-31","value":-730.15,"profit":false},{"date":"2024-12-31","value":100,"profit":true}] |
| Total Non-Operating Income/Expense | - | (457.15K) | (4.91M) | (810.00K) | (3.66M) | [{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":-45714800,"profit":false},{"date":"2022-12-31","value":-491000000,"profit":false},{"date":"2023-12-31","value":-81000000,"profit":false},{"date":"2024-12-31","value":-365525100,"profit":false}] |
| Pre-Tax Income | (1.14M) | (3.87M) | (7.88M) | (4.41M) | (2.05M) | [{"date":"2020-12-31","value":-114101300,"profit":false},{"date":"2021-12-31","value":-386721700,"profit":false},{"date":"2022-12-31","value":-787600000,"profit":false},{"date":"2023-12-31","value":-440700000,"profit":false},{"date":"2024-12-31","value":-205158700,"profit":false}] |
| Income Taxes | (104.34K) | 15.01K | (621.00K) | - | 33.00 | [{"date":"2020-12-31","value":-695.35,"profit":false},{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":-4138.62,"profit":false},{"date":"2023-12-31","value":"-","profit":true},{"date":"2024-12-31","value":0.22,"profit":true}] |
| Income After Taxes | - | (3.88M) | (7.25M) | - | (2.05M) | [{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":-388222200,"profit":false},{"date":"2022-12-31","value":-725500000,"profit":false},{"date":"2023-12-31","value":"-","profit":true},{"date":"2024-12-31","value":-205162000,"profit":false}] |
| Income From Continuous Operations | - | (7.25M) | (7.25M) | (4.41M) | (24.77M) | [{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":-725500000,"profit":false},{"date":"2022-12-31","value":-725500000,"profit":false},{"date":"2023-12-31","value":-440700000,"profit":false},{"date":"2024-12-31","value":-2477000000,"profit":false}] |
| Income From Discontinued Operations | - | - | - | - | - | [{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true},{"date":"2024-12-31","value":"-","profit":true}] |
| Net Income | (760.07K) | (3.87M) | (7.05M) | (4.34M) | (2.05M) | [{"date":"2020-12-31","value":-76006900,"profit":false},{"date":"2021-12-31","value":-386721700,"profit":false},{"date":"2022-12-31","value":-705100000,"profit":false},{"date":"2023-12-31","value":-433600000,"profit":false},{"date":"2024-12-31","value":-205158700,"profit":false}] |
| EPS (Diluted) | - | - | - | - | (1.99) | [{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true},{"date":"2024-12-31","value":-199.08,"profit":false}] |
These ratios help you determine the liquidity of the company. Higher is better.
| IBO | |
|---|---|
| Cash Ratio | 0.00 |
| Current Ratio | 0.04 |
| Quick Ratio | 0.02 |
These ratios help you understand the company's efficiency in using its assets to generate returns. Higher is better. For ROE, average long term is around 14%, less than 10% is poor.
| IBO | |
|---|---|
| ROA (LTM) | -7.68% |
| ROE (LTM) | -346.99% |
These ratios help you understand the company's liabilities, gauging the riskiness of the investment.
| IBO | |
|---|---|
| Debt Ratio Lower is generally better. Negative is bad. | 1.49 |
| Common Equity/Total Assets Higher is better. Lower can suggest investment is riskier. | -0.65 |
These ratios help you understand the company's valuation. Lower may indicate cheaper stocks.
| IBO | |
|---|---|
| Trailing PE | NM |
| Forward PE | NM |
| P/S (TTM) | 1841.33 |
| P/B | 1.24 |
| Price/FCF | NM |
| EV/R | 2781.93 |
| EV/Ebitda | 4.72 |
Impact BioMedical, Inc. (IBO) share price today is $0.415
Yes, Indians can buy shares of Impact BioMedical, Inc. (IBO) on Vested. To buy
Yes, you can purchase fractional shares of Impact BioMedical, Inc. (IBO) via the Vested app. You can start investing in Impact BioMedical, Inc. (IBO) with a minimum investment of $1.
You can invest in shares of Impact BioMedical, Inc. (IBO) via Vested in three simple steps:
The 52-week high price of Impact BioMedical, Inc. (IBO) is $6.17. The 52-week low price of Impact BioMedical, Inc. (IBO) is $0.36.
The price-to-earnings (P/E) ratio of Impact BioMedical, Inc. (IBO) is
The price-to-book (P/B) ratio of Impact BioMedical, Inc. (IBO) is 1.24
The dividend yield of Impact BioMedical, Inc. (IBO) is 0.00%
The market capitalization of Impact BioMedical, Inc. (IBO) is $46.17M
The stock symbol (or ticker) of Impact BioMedical, Inc. is IBO
Consider the share price of Impact BioMedical, Inc. as a long-term story and not a daily point list. The price represents a movement of the stock in both good and bad times when looked at over many years. This assists the investors to know whether Impact BioMedical, Inc. has succeeded to expand steadily and overcome market declines. With this price movement observed and the way the business is progressing, it is easier to make a decision whether the stock is worth having in the long term or not.
When investing in Impact BioMedical, Inc. shares, you are not based in India then your investment is not just based on the stock price. It is also determined by the currency movement of the dollar in relation to the rupee. When you have an appreciation of the Impact BioMedical, Inc. stock and the dollar appreciation is also the same, you gain more in terms of rupees. When the rupee appreciated, it will lower your profits. This currency flow is a silent cause of great contribution to your ultimate returns over many years.
Rather than merely checking the share price of Impact BioMedical, Inc. and comparing it with that of other stocks in the same sector, one can check how robust the business is. Investors tend to compare such aspects as profits, cash generation, and the stability of the revenues of the company. This means that Impact BioMedical, Inc. stock in most cases does not react in the same manner as other companies in the sector due to its brand and services revenue.
Link copied 
